FDA limits Timeframe for Responding to a 483

When deficiencies are found during an inspection, they are noted in a so-called form 483 (483 is the number of the form used). The report is handed out by the investigator at the end of the inspection. In the past, some firms only responded to parts of these reports or sent an official response with a delay of several weeks. In a new programme starting on 15 September 2009, the FDA intends to set the timeframe for statements and responses to a 483 to a maximum of 15 business days. It is the aim of this measure to enable the agency to issue Warning Letters more rapidly if necessary. A Warning Letter is issued in case of serious deviations, but also if a written response to the 483 report is considered inadequate. In the future, if the FDA receives the written response to the 483 within the set period, the response will be reviewed in detail before a Warning Letter might be issued. Should the response arrive later, the Warning Letter can be issued independently of it, and the firm's statement will not be taken into consideration. The programme is planned to run 18 months. After this phase, the FDA will decide whether the new regulation remains in force unchanged or whether it is modified. Further information: Docket No. FDA-2009-N-0335: Review of Post-Inspection

Responses
Wolfgang Schmitt
On behalf of the European Compliance Academy (ECA)

---

Other Related News

• GPMA holds a Workshop with MHRA - 15 Oct '11
• Limiting of Paracetamol in fixed dose combinations - 22 Dec '11
• One Day Technical Seminar on Good Quality Practices held - 26 Apr '10
• Indian Pharmacopoeia Commission releases Pharmacopoeia 2010 edition - 10 Aug '10
• EXTRACT FROM SURVEY OF SPURIOUS DRUG REPORT - 01 Sep '10
• MORMUGAO TO BE NOTIFIED AS PHARMA PORT - 27 Sep '10
• Formation of New Executive Committee - 08 Nov '11
• Sub-Zonal Office of DCGI West Zone starts functioning at Mormugao Port - 16 Nov '11
• FIRST CONSIGNMENT OF PHARMA EXPORT FROM MORMUGAO PORT FLAGGED OFFFLAGGED - 22 Dec '11
• WORKSHOP ON MANAGEMENT OF INTELLECTUAL PROPERTY RIGHTS TO BE HELD BY GPMA - 12 Mar '12
• NEW EXECUTIVE COMMITTEE TAKES OVER - 01 Apr '12
• GPMA Logistics Seminar - Taj Vivanta on 24th Nov - 24 Nov '12
• GPMA & Indian Pharmaceutical Association Seminar - 8th September, 2014 - 25 Aug '14
• MHRA SEMINAR ON DATA INTEGRITY ISSUES IN PHARMA INDUSTRY - UNDERSTANDING AND RESOLUTION - 11 Sep '14
• Medical Health Check up camp for detection of Diabetes, Hypertension and Blood Group - 04 Feb '15
• PHARMA INDUSTRY IN GOA- FUTURE - 29 May '15
• GPMA & IDMA PROGRAM ON NEW INSIGHTS ON TABLET MANUFACTURING AND TESTING - 03 Oct '15
• DEPUTY CM APEALS TO PHARMA COMPANIES IN GOA FOR DEVELOPMENTAL ACTIVITIES THROUGH CSR - 02 Jul '16
• GPMA – Change of Guard - 11 Aug '18
• Global Pharma Market And Indian Pharmaceutical Industry an overview By Dr. Praveen Khullar, GPMA - 11 Aug '18
• GPMA HOLDS INDUSTRY ACADEMIA INTERACTION - 08 Dec '18
• GPMA holds seminar on Understanding USP Monographs by Zeenat Khan, Senior Manager – Strategic Customer Development, USP, Hyderabad - 26 Feb '19
• Vibrant Goa conducted Road show in association of GPMA - 09 Sep '19
• INTERACTION WITH GPMA MEMBERS FDA Office, Bambolim Goa - 09 Sep '19
• CII GOA Conference on HEALTHCARE & PHARMA - 09 Sep '19
• GPMA holds industry-academia meet - 09 Sep '19
• Annual General Body meeting of Goa Pharmaceuticals Manufacturers Association [ GPMA] - 19 Sep '19
• GPMA Participation at Vibrant Goa Expo - 30 Oct '19
• Meeting with the Drugs Controller General (India) held on 11th November 2019 at Taj Exotica, Goa. - 14 Nov '19
• Goa Pharmaceuticals Manufacturers Association participated in Vanijya Utsav - 03 Nov '21
• Goa Pharmaceuticals Manufacturers Association felicitated Ms. Medha Desai, Deputy Director - 03 Nov '21